Clinical Trial Update: Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial investigating pembrolizumab in combination with tamoxifen for advanced hormone receptor-positive breast cancer with ESR1 mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Mediclinic Middle East | Conditions: Breast Cancer Female | Phase 2 | Status: UNKNOWN